Answers are grounded in this paper and cite their sources.
Glucose-conjugated malonato-platinum(II) complexes are designed and synthesized to target tumor-specific active transporters, namely, glucose transporters (GLUTs); the complexes exhibit much higher aqueous solubility by 150 times, improved potency in cytotoxicities by 10 times, and increased therapeutic index by over 30 fold compared to the newest generation of clinical drugs oxaliplatin.
No takes yet. Share an insight, caveat, or question.
Liu et al. (2013) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: